Abstract
The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing around the world, in association with the progressive elevation in overweight and obesity. The accumulation of lipids in NAFLD patients contributes to the development of insulin resistance, inflammation and oxidative stress in hepatocytes, and alteration of blood lipids and glycaemia. There are currently no effective pharmacological therapies for NAFLD, although lifestyle and dietary modifications targeting weight reduction are among the prevailing alternative approaches. For this reason, new approaches should be investigated. The natural polyphenol resveratrol represents a potential new treatment for management of NAFLD due to anti-inflammatory and antioxidant properties. Although preclinical trials have demonstrated promising results of resveratrol against NALFD, the lack of conclusive results creates the need for more trials with larger numbers of patients, longer time courses, and standardized protocols.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34(3):274–285
Adams LA, Anstee QM, Tilg H, Targher G (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66(6):1138–1153
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55(6):2005–2023
Theodotou M, Fokianos K, Moniatis D, Kadlenic R, Chrysikou A, Aristotelous A et al (2019) Effect of resveratrol on non-alcoholic fatty liver disease. Exp Ther Med 18(1):559–565
Lu FB, Hu ED, Xu LM, Chen L, Wu JL, Li H et al (2018) The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 12(5):491–502
Polyzos SA, Kountouras J, Mantzoros CS (2017) Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol 42(2):92–108
Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A (2017) Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 23(47):8263–8276
Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH (2010) The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 30(6):795–808
Gu Y, Lambert JD (2013) Modulation of metabolic syndrome-related inflammation by cocoa. Mol Nutr Food Res 57(6):948–961
Rodriguez-Mateos A, Vauzour D, Krueger CG, Shanmuganayagam D, Reed J, Calani L et al (2014) Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update. Arch Toxicol 88(10):1803–1853
Springer M, Moco S (2019) Resveratrol and its human metabolites-effects on metabolic health and obesity. Nutrients 11(1):143. https://doi.org/10.3390/nu11010143
Burns J, Yokota T, Ashihara H, Lean ME, Crozier A (2002) Plant foods and herbal sources of resveratrol. J Agric Food Chem 50(11):3337–3340
Smoliga JM, Vang O, Baur JA (2012) Challenges of translating basic research into therapeutics: resveratrol as an example. J Gerontol A Biol Sci Med Sci 67(2):158–167
Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F et al (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127(6):1109–1122
Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ et al (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15(5):675–690
Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346(16):1221–1231
Clark JM (2006) The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 40:S5–S10
Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62(1):S47–S64
Saviano MC, Brunetti F, Rubino A, Franzese A, Vajro P, Argenziano A et al (1997) Liver involvement in obese children (ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population). Dig Dis Sci 42(7):1428–1432
Bellentani S, Scaglioni F, Marino M, Bedogni G (2010) Epidemiology of non-alcoholic fatty liver disease. Dig Dis 28(1):155–161
Berlanga A, Guiu-Jurado E, Porras JA, Auguet T (2014) Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 7:221–239
Serviddio G, Bellanti F, Vendemiale G (2013) Free radical biology for medicine: learning from nonalcoholic fatty liver disease. Free Radic Biol Med 65:952–968
Gupte AA, Lyon CJ, Hsueh WA (2013) Nuclear factor (erythroid-derived 2)-like-2 factor (Nrf2), a key regulator of the antioxidant response to protect against atherosclerosis and nonalcoholic steatohepatitis. Curr Diab Rep 13(3):362–371
Gutteridge JM, Halliwell B (1992) Comments on review of free radicals in biology and medicine, by Barry Halliwell and John MC Gutteridge. Free Radic Biol Med 12(1):93–95
Ashraf NU, Sheikh TA (2015) Endoplasmic reticulum stress and oxidative stress in the pathogenesis of non-alcoholic fatty liver disease. Free Radic Res 49(12):1405–1418
Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52(5):1836–1846
Schwabe RF, Uchinami H, Qian T, Bennett BL, Lemasters JJ, Brenner DA (2004) Differential requirement for c-Jun NH2-terminal kinase in TNFα- and Fas-mediated apoptosis in hepatocytes. FASEB J 18(6):720–722
Pahl HL (1999) Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18(49):6853–6866
Diehl AM (2004) Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 8(3):619–638
Ricapa JG, Grueso RL, González GO, de la Torre MI, Abdelazid K, El Alami M et al (2013) Resveratrol: distribution, properties and perspectives. Rev Esp Geriatr Gerontol 48(2):79–88
Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L (2004) Polyphenols: food sources and bioavailability. Am J Clin Nutr 79(5):727–747
Salvador I, Massarioli AP, Silva AP, Malaguetta H, Melo PS, Alencar SM (2019) Can we conserve trans-resveratrol content and antioxidant activity during industrial production of chocolate? J Sci Food Agric 99(1):83–89
Lancon A, Delma D, Osman H, Thénot JP, Jannin B, Latruffe N (2004) Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun 316(4):1132–1137
Wang P, Sang S (2018) Metabolism and pharmacokinetics of resveratrol and pterostilbene. Biofactors 44(1):16–25
Wu T, Grootaert C, Voorspoels S, Jacobs G, Pitart J, Kamiloglu S et al (2017) Aronia (Aroniamelanocarpa) phenolics bioavailability in a combined in vitro digestion/Caco-2 cell model is structure and colon region dependent. J Funct Foods 38:128–139
Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi PP et al (2005) Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 49(5):495–504
Wenzel E, Somoza V (2005) Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 49(5):472–481
Amri A, Chaumeil JC, Sfar S, Charrueau C (2012) Administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release 158(2):182–193
Huang XT, Li X, Xie ML, Huang Z, Huang YX, Wu GX et al (2019) Resveratrol: review on its discovery, anti-leukemia effects, pharmacokinetics. Chem Biol Interact 306:29–38
Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA et al (2010) Resveratrol modulates drugandcarcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3(9):1168–1175
Izdebska M, Piątkowska-Chmiel I, Korolczuk A, Herbet M, Gawrońska-Grzywacz M, Gieroba R et al (2017) The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells. Can J Physiol Pharmacol 95(12):1442–1453
Izdebska M, Herbet M, Gawrońska-Grzywacz M, Piątkowska-Chmiel I, Korga A, Sysa M et al (2018) Resveratrol limits lipogenesis and enhance mitochondrial activity in HepG2 cells. J Pharm Pharm Sci 21(1):504–515
Rafiei H, Omidian K, Bandy B (2017) Comparison of dietary polyphenols for protection against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of steatosis. Mol Nutr Food Res 61(9). https://doi.org/10.1002/mnfr.201600781
Li YH, Choi DH, Lee EH, Seo SR, Lee S, Cho EH (2016) Sirtuin 3 (SIRT3) regulates α-smooth muscle actin (α-SMA) production through the succinate dehydrogenase-G protein-coupled receptor 91 (GPR91) pathway in hepatic stellate cells. J Biol Chem 291(19):10277–10292
Huang Y, Lang H, Chen K, Zhang Y, Gao Y, Ran L et al (2020) Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway. Appl Physiol Nutr Metab 45(3):227–239
Bujanda L, Hijona E, Larzabal M, Beraza M, Aldazabal P, GarcÃa-Urkia N et al (2008) Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 8:40. https://doi.org/10.1186/1471-230X-8-40
Poulsen MM, Larsen JØ, Hamilton-Dutoit S, Clasen BF, Jessen N, Paulsen SK et al (2012) Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutr Res 32(9):701–708
Andrade JMO, ParaÃso AF, de Oliveira MVM, Martins AME, Neto JF, Guimarães ALS et al (2014) Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition 30(7-8):915–919
Ali MH, Messiha BA, Abdel-Latif HA (2016) Protective effect of ursodeoxycholic acid, resveratrol, and N acetylcysteine on nonalcoholic fatty liver disease in rats. Pharm Biol 54(7):1198–1208
Khaleel EF, Abdel-Aleem GA, Mostafa DG (2018) Resveratrol improves high-fat diet induced fatty liver and insulin resistance by concomitantly inhibiting proteolytic cleavage of sterol regulatory element binding proteins, free fatty acid oxidation, and intestinal triglyceride absorption. Can J Physiol Pharmacol 96(2):145–157
Xu K, Liu S, Zhao X, Zhang X, Fu X, Zhou Y et al (2019) Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol. Biomed Pharmacother 110:844–849
Kessoku T, Imajo K, Honda Y, Kato T, Ogawa Y, Tomeno W et al (2016) Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis. Sci Rep 6:22251. https://doi.org/10.1038/srep22251
Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O’Moore-Sullivan TM, Lee P et al (2014) Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Nutr Res 12(12):2092–2103
Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A (2014) Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res 34(10):837–843
Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, Poulsen MK, Stødkilde-Jørgensen H, Møller HJ et al (2016) Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol 51(4):456–464
Asghari S, Rafraf M, Farzin L, Asghari-Jafarabadi M, Ghavami SM, Somi MH (2018) Effects of pharmacologic dose of resveratrol supplementation on oxidative/antioxidative status biomarkers in nonalcoholic fatty liver disease patients: a randomized, double-blind, placebo-controlled trial. Adv Pharm Bull 8(2):307–317
Kantartzis K, Fritsche L, Bombrich M, Machann J, Schick F, Staiger H et al (2018) Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Obes Metab 20(7):1793–1797
Poulsen MK, Nellemann B, Bibby BM, Stødkilde-Jørgensen H, Pedersen SB, Grønbæk H et al (2018) No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease. Diabetes Obes Metab 20(10):2504–2509
Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y et al (2015) Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis 47(3):226–232
Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C et al (2008) Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 27(5):412–421
Chu CJ, Lu RH, Wang SS, Chang FY, Wu SL, Lu CL et al (2007) Risk factors associated with non-alcoholic fatty liver disease in Chinese patients and the role of tumor necrosis factor-alpha. Hepato-Gastroenterology 54(79):2099–2102
Ji G, Wang Y, Deng Y, Li X, Jiang Z (2015) Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy. Lipids Health Dis 14(1):134. https://doi.org/10.1186/s12944-015-0139-6
Liu Z, Jiang C, Zhang J, Liu B, Du Q (2016) Resveratrol inhibits inflammation and ameliorates insulin resistant endothelial dysfunction via regulation of AMP-activated protein kinase and sirtuin 1 activities. J Diabetes 8(3):324–335
Suenaga F, Hatsushika K, Takano S, Ando T, Ohnuma Y, Ogawa H et al (2008) A possible link between resveratrol and TGF-β: resveratrol induction of TGF-β expression and signaling. FEBS Lett 582(5):586–590
Tilg H, Moschen AR, Szabo G (2016) Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 64(3):955–965
Yang SJ, Lim Y (2014) Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. Metabolism 63(5):693–701
Manna SK, Mukhopadhyay A, Aggarwal BB (2000) Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164(12):6509–6519
Li L, Hai J, Li Z, Zhang Y, Peng H, Li K et al (2014) Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol 63:166–173
Ma C, Wang Y, Dong L, Li M, Cai W (2015) Anti-inflammatory effect of resveratrol through the suppression of NF-κB and JAK/STAT signaling pathways. Acta Biochim Biophys Sin Shanghai 47(3):207–213
Shi SY, Martin RG, Duncan RE, Choi D, Lu SY, Schroer SA et al (2012) Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance. J Biol Chem 287(13):10277–10288
Sumida Y, Niki E, Naito Y, Yoshikawa T (2013) Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res 47(11):869–880
Gómez-Zorita S, Fernández-Quintela A, Macarulla MT, Aguirre L, Hijona E, Bujanda L et al (2012) Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr 107(2):202–210
Tang Y, Xu J, Qu W, Peng X, Xin P, Yang X et al (2012) Resveratrol reduces vascular cell senescence through attenuation of oxidative stress by SIRT1/NADPH oxidase-dependent mechanisms. J Nutr Biochem 23(11):1410–1416
Subauste AR, Burant CF (2007) Role of FoxO1 in FFA-induced oxidative stress in adipocytes. Am J Physiol Endocrinol Metab 293(1):E159–E164
Zhu W, Chen S, Li Z, Zhao X, Li W, Sun Y et al (2014) Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice. Nutr Metab (Lond) 11(1):35. https://doi.org/10.1186/1743-7075-11-35
Hori YS, Kuno A, Hosoda R, Horio Y (2013) Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS One 8(9):e73875. https://doi.org/10.1371/journal.pone.0073875
Spanier G, Xu H, Xia N, Tobias S, Deng S, Wojnowski L et al (2009) Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol 60(Suppl 4):111–116
Chen F, Qian LH, Deng B, Liu ZM, Zhao Y, Le YY (2013) Resveratrol protects vascular endothelial cells from high glucose–induced apoptosis through inhibition of NADPH oxidase activation–driven oxidative stress. CNS Neurosci Ther 19(9):675–681
Choi YJ, Suh HR, Yoon Y, Lee KJ, Kim DG, Kim S et al (2014) Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase. Arch Pharm Res 37(9):1169–1176
Ajmo JM, Liang X, Rogers CQ, Pennock B, You M (2008) Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 295(4):G833–G842
Jeon SM, Lee SA, Choi MS (2014) Antiobesity and vasoprotective effects of resveratrol in apoE-deficient mice. J Med Food 17(3):310–316
Xin P, Han H, Gao D, Cui W, Yang X, Ying C et al (2013) Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. Food Chem Toxicol 52:12–18
Momchilova A, Petkova D, Staneva G, Markovska T, Pankov R, Skrobanska R et al (2014) Resveratrol alters the lipid composition, metabolism and peroxide level in senescent rat hepatocytes. Chem Biol Interact 207:74–80
Nagle CA, Klett EL, Coleman RA (2009) Hepatic triacylglycerol accumulation and insulin resistance. J Lipid Res 50(Supplement):S74–S79
Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, Lan F et al (2010) AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab 298(4):E751–E760
Houtkooper RH, Pirinen E, Auwerx J (2012) Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 13(4):225–238
Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H et al (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148(3):421–433
Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC et al (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458(7241):1056–1060
Kang W, Hong HJ, Guan J, Kim DG, Yang EJ, Koh G et al (2012) Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents. Metabolism 61(3):424–433
Burgess TA, Robich MP, Chu LM, Bianchi C, Sellke FW (2011) Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle. Arch Surg 146(5):556–564
Vetterli L, Brun T, Giovannoni L, Bosco D, Maechler P (2011) Resveratrol potentiates glucose-stimulated insulin secretion in INS-1E β-cells and human islets through a SIRT1-dependent mechanism. J Biol Chem 286(8):6049–6060
Zhang J, Chen L, Zheng J, Zeng T, Li H, Xiao H et al (2012) The protective effect of resveratrol on islet insulin secretion and morphology in mice on a high-fat diet. Diabetes Res Clin Pract 97(3):474–482
Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H (2008) Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 29(6):698–706
Ma J, Zhou Q, Li H (2017) Gut microbiota and nonalcoholic fatty liver disease: insights on mechanisms and therapy. Nutrients 9(10):1124. https://doi.org/10.3390/nu9101124
Abu-Shanab A, Quigley EM (2010) The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7(12):691–701
Cani PD, Delzenne NM (2007) Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care 10(6):729–734
Campbell CL, Yu R, Li F, Zhou Q, Chen D, Qi C et al (2019) Modulation of fat metabolism and gut microbiota by resveratrol on high-fat diet-induced obese mice. Diabetes Metab Syndr Obes 12:97–107
Wang P, Li D, Ke W, Liang D, Hu X, Chen F (2020) Resveratrol-induced gut microbiota reduces obesity in high-fat diet-fed mice. Int J Obes 44(1):213–225
Etxeberria U, Arias N, Boqué N, Macarulla MT, Portillo MP, MartÃnez JA et al (2015) Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats. J Nutr Biochem 26(6):651–660
Slocum SL, Skoko JJ, Wakabayashi N, Aja S, Yamamoto M, Kensler TW et al (2016) Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet. Arch Biochem Biophys 591:57–65
Chambel SS, Santos-Gonçalves A, Duarte TL (2015) The dual role of Nrf2 in nonalcoholic fatty liver disease: regulation of antioxidant defenses and hepatic lipid metabolism. Biomed Res Int 2015:597134. https://doi.org/10.1155/2015/597134
Uruno A, Yagishita Y, Yamamoto M (2015) The Keap1–Nrf2 system and diabetes mellitus. Arch Biochem Biophys 566:76–84
Palsamy P, Subramanian S (2011) Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2–Keap1 signaling. Biochim Biophys Acta 1812(7):719–731
Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, Pearson K et al (2010) Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 299(1):H18–H24
Rubiolo JA, Mithieux G, Vega FV (2008) Resveratrol protects primary rat hepatocytes against oxidative stress damage:: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur J Pharmacol 591(1-3):66–72
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Karimi, M., Abiri, B., Guest, P.C., Vafa, M. (2022). Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications. In: Guest, P.C. (eds) Physical Exercise and Natural and Synthetic Products in Health and Disease. Methods in Molecular Biology, vol 2343. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1558-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1558-4_2
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1557-7
Online ISBN: 978-1-0716-1558-4
eBook Packages: Springer Protocols